Annual CFO
-$247.58 M
-$132.36 M-114.87%
December 31, 2024
Summary
- As of March 12, 2025, IDYA annual cash flow from operations is -$247.58 million, with the most recent change of -$132.36 million (-114.87%) on December 31, 2024.
- During the last 3 years, IDYA annual CFO has fallen by -$191.81 million (-343.87%).
- IDYA annual CFO is now -546.39% below its all-time high of $55.46 million, reached on December 31, 2020.
Performance
IDYA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$121.66 M
-$72.42 M-147.10%
December 31, 2024
Summary
- As of March 12, 2025, IDYA quarterly cash flow from operations is -$121.66 million, with the most recent change of -$72.42 million (-147.10%) on December 31, 2024.
- Over the past year, IDYA quarterly CFO has dropped by -$77.84 million (-177.67%).
- IDYA quarterly CFO is now -234.86% below its all-time high of $90.21 million, reached on September 30, 2020.
Performance
IDYA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$247.58 M
-$97.91 M-65.41%
December 31, 2024
Summary
- As of March 12, 2025, IDYA TTM cash flow from operations is -$247.58 million, with the most recent change of -$97.91 million (-65.41%) on December 31, 2024.
- Over the past year, IDYA TTM CFO has dropped by -$116.39 million (-88.71%).
- IDYA TTM CFO is now -524.29% below its all-time high of $58.35 million, reached on September 30, 2020.
Performance
IDYA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
IDYA Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -114.9% | -177.7% | -88.7% |
| 3 y3 years | -343.9% | -177.7% | -88.7% |
| 5 y5 years | -529.8% | -177.7% | -88.7% |
IDYA Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -343.9% | at low | -630.4% | at low | -343.9% | at low |
| 5 y | 5-year | -546.4% | at low | -234.9% | at low | -524.3% | at low |
| alltime | all time | -546.4% | at low | -234.9% | at low | -524.3% | at low |
IDEAYA Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$247.58 M(+114.9%) | -$121.66 M(+147.1%) | -$247.58 M(+65.4%) |
| Sep 2024 | - | -$49.23 M(+49.7%) | -$149.68 M(+14.6%) |
| Jun 2024 | - | -$32.88 M(-24.9%) | -$130.62 M(-0.4%) |
| Mar 2024 | - | -$43.81 M(+84.5%) | -$131.19 M(+13.9%) |
| Dec 2023 | -$115.22 M(+32.2%) | -$23.75 M(-21.3%) | -$115.22 M(+0.3%) |
| Sep 2023 | - | -$30.17 M(-9.8%) | -$114.85 M(+5.5%) |
| Jun 2023 | - | -$33.46 M(+20.2%) | -$108.84 M(+14.1%) |
| Mar 2023 | - | -$27.84 M(+19.1%) | -$95.37 M(+9.4%) |
| Dec 2022 | -$87.17 M(+56.3%) | -$23.37 M(-3.3%) | -$87.17 M(+8.3%) |
| Sep 2022 | - | -$24.17 M(+20.9%) | -$80.46 M(+17.0%) |
| Jun 2022 | - | -$19.99 M(+1.8%) | -$68.76 M(+11.4%) |
| Mar 2022 | - | -$19.65 M(+18.0%) | -$61.70 M(+10.6%) |
| Dec 2021 | -$55.78 M | -$16.66 M(+33.6%) | -$55.78 M(+10.0%) |
| Sep 2021 | - | -$12.47 M(-3.6%) | -$50.72 M(-197.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$12.93 M(-5.8%) | $51.96 M(+1.3%) |
| Mar 2021 | - | -$13.72 M(+18.4%) | $51.28 M(-7.5%) |
| Dec 2020 | $55.46 M(-241.1%) | -$11.60 M(-112.9%) | $55.46 M(-5.0%) |
| Sep 2020 | - | $90.21 M(-763.0%) | $58.35 M(-237.6%) |
| Jun 2020 | - | -$13.61 M(+42.5%) | -$42.41 M(+8.5%) |
| Mar 2020 | - | -$9.54 M(+9.6%) | -$39.07 M(-0.6%) |
| Dec 2019 | -$39.31 M(+42.3%) | -$8.71 M(-17.5%) | -$39.31 M(+3.2%) |
| Sep 2019 | - | -$10.55 M(+2.7%) | -$38.08 M(+5.1%) |
| Jun 2019 | - | -$10.27 M(+5.0%) | -$36.23 M(+13.6%) |
| Mar 2019 | - | -$9.79 M(+30.9%) | -$31.88 M(+15.4%) |
| Dec 2018 | -$27.62 M(+125.9%) | -$7.48 M(-14.0%) | -$27.62 M(+37.1%) |
| Sep 2018 | - | -$8.69 M(+46.7%) | -$20.14 M(+75.9%) |
| Jun 2018 | - | -$5.93 M(+7.2%) | -$11.45 M(+107.2%) |
| Mar 2018 | - | -$5.53 M | -$5.53 M |
| Dec 2017 | -$12.22 M | - | - |
FAQ
- What is IDEAYA Biosciences annual cash flow from operations?
- What is the all time high annual CFO for IDEAYA Biosciences?
- What is IDEAYA Biosciences annual CFO year-on-year change?
- What is IDEAYA Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for IDEAYA Biosciences?
- What is IDEAYA Biosciences quarterly CFO year-on-year change?
- What is IDEAYA Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for IDEAYA Biosciences?
- What is IDEAYA Biosciences TTM CFO year-on-year change?
What is IDEAYA Biosciences annual cash flow from operations?
The current annual CFO of IDYA is -$247.58 M
What is the all time high annual CFO for IDEAYA Biosciences?
IDEAYA Biosciences all-time high annual cash flow from operations is $55.46 M
What is IDEAYA Biosciences annual CFO year-on-year change?
Over the past year, IDYA annual cash flow from operations has changed by -$132.36 M (-114.87%)
What is IDEAYA Biosciences quarterly cash flow from operations?
The current quarterly CFO of IDYA is -$121.66 M
What is the all time high quarterly CFO for IDEAYA Biosciences?
IDEAYA Biosciences all-time high quarterly cash flow from operations is $90.21 M
What is IDEAYA Biosciences quarterly CFO year-on-year change?
Over the past year, IDYA quarterly cash flow from operations has changed by -$77.84 M (-177.67%)
What is IDEAYA Biosciences TTM cash flow from operations?
The current TTM CFO of IDYA is -$247.58 M
What is the all time high TTM CFO for IDEAYA Biosciences?
IDEAYA Biosciences all-time high TTM cash flow from operations is $58.35 M
What is IDEAYA Biosciences TTM CFO year-on-year change?
Over the past year, IDYA TTM cash flow from operations has changed by -$116.39 M (-88.71%)